Nateglinide

Revision as of 14:11, 20 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Jump to navigation Jump to search


Nateglinide
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
ATC code
Pharmacokinetic data
Protein binding98%
Elimination half-life1.5 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H27NO3
Molar mass317.423 g/mol

WikiDoc Resources for Nateglinide

Articles

Most recent articles on Nateglinide

Most cited articles on Nateglinide

Review articles on Nateglinide

Articles on Nateglinide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nateglinide

Images of Nateglinide

Photos of Nateglinide

Podcasts & MP3s on Nateglinide

Videos on Nateglinide

Evidence Based Medicine

Cochrane Collaboration on Nateglinide

Bandolier on Nateglinide

TRIP on Nateglinide

Clinical Trials

Ongoing Trials on Nateglinide at Clinical Trials.gov

Trial results on Nateglinide

Clinical Trials on Nateglinide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nateglinide

NICE Guidance on Nateglinide

NHS PRODIGY Guidance

FDA on Nateglinide

CDC on Nateglinide

Books

Books on Nateglinide

News

Nateglinide in the news

Be alerted to news on Nateglinide

News trends on Nateglinide

Commentary

Blogs on Nateglinide

Definitions

Definitions of Nateglinide

Patient Resources / Community

Patient resources on Nateglinide

Discussion groups on Nateglinide

Patient Handouts on Nateglinide

Directions to Hospitals Treating Nateglinide

Risk calculators and risk factors for Nateglinide

Healthcare Provider Resources

Symptoms of Nateglinide

Causes & Risk Factors for Nateglinide

Diagnostic studies for Nateglinide

Treatment of Nateglinide

Continuing Medical Education (CME)

CME Programs on Nateglinide

International

Nateglinide en Espanol

Nateglinide en Francais

Business

Nateglinide in the Marketplace

Patents on Nateglinide

Experimental / Informatics

List of terms related to Nateglinide

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs and is sold by Novartis.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the ß cells. This depolarizes the ß cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

External links

Template:Oral hypoglycemics


Template:WikiDoc Sources